Mammalian target of rapamycin (mTOR) inhibitors are currently considered an alternative immunosuppressive treatment that can prevent the nephrotoxicity, viral infections and malignancies that are associated with calcineurin inhibitor-based immunosuppressive regimens. However, the side eff ects of mTOR-inhibitor-based regimens lead to frequent treatment discontinuations, and not all patients seem to have the same benefi ts from conversion to mTOR inhibitors. This review focuses on long-term results of trials that have assessed early and late conversion to sirolimus or everolimus. The renal benefi t of late conversion (≥1 year post transplantation) is limited, except in patients with good renal function and without proteinuria. Early conversion to mTOR inhibitors in the fi rst 6 months, in combination with mycophenolate mofetil, could be an appropriate strategy for maintenance therapy in renal transplant recipients with a low immunological risk after careful screening at the time of conversion. Good renal function (glomerular fi ltration rate >40 ml/ minute), weak proteinuria (<1 g/day), an absence of previous acute rejection and subclinical rejection, and appearance of donor-specifi c anti-human leukocyte antigen antibodies appear to be the most important criteria in identifying patients for whom conversion to an mTOR inhibitor may improve renal function at 5 years.
Introduction
Signifi cant progress in organ transplantation in the past two decades has been mostly driven by improvement of short-term graft and patient survival due, in particular, to the use of calcineurin inhibitors (CNIs), which have reduced the rate of acute rejection considerably [1] . Nevertheless, this improvement in graft survival in the fi rst year after transplantation has had a limited impact on long-term outcomes, which has only slowly improved [2] . Th is limited impact can be explained in part by the serious chronic adverse events associated with the use of CNIs, such as the increased risk of malignancies and cardiovascular events, which are the most frequent causes of death in kidney transplant patients. Importantly, CNIs also contribute to the development of chronic graft injuries [3] . Data suggest that CNI-sparing regimens could improve long-term graft and patient survival, as shown by Gallagher and colleagues, who reported improved 20-year graft survival in patients in whom cyclosporine (CsA) had been converted to azathioprine 3 months after trans plantation in comparison with patients who continued CsA [4] .
Th e advent of new immunosuppressive agents, such as mTOR inhibitors, has allowed CNI-based regimens to be used sparingly, and tests the hypothesis that CNIs contribute to chronic allograft nephropathy [5, 6] . Sirolimus (SRL) binds to the mTOR complex and inhibits immune cell proliferation and diff erentiation. A pioneering trial of CNI withdrawal from SRL-based therapy demonstrated improved 4-year graft survival with improved renal function [7] , showing that maintenance therapy with SRL and mycophenolate mofetil (MMF) was eff ective, thus paving the way to conversion strategies.
Late conversion
In the CONVERT study, 830 patients were randomised 6 to 120 months after transplantation (mean 3.1 years) with a 2:1 ratio to either convert to SRL or to continue on a CNI (cyclosporine or tacrolimus) [8] . In addition, patients received steroids and adapted doses of either MMF or azathioprine. Th e primary endpoints were renal function, evaluated by the Nankivell glomerular fi ltration rate (GFR), and the cumulative rates of biopsy-proved acute rejection (BPAR), graft loss, or death at 12 months. Patients were stratifi ed by baseline GFR: either 20 to 40 ml/minute or >40 ml/minute. Intent-to-treat analyses at 12 and 24 months showed no signifi cant treatment diff erences in GFR. Th e mean GFR at 12 and 24 months was signifi cantly higher in the group converted to SRL in comparison with the CNI group for patients with baseline GFR >40 ml/minute who remained on assigned therapy (63.6 vs. 61.1 ml/minute, P = 0.006 and 62.6 vs. 59.9 ml/minute, P = 0.009, at 12 and 24 months respectively) and for the subgroup with baseline GFR >40 ml/ minute and a urinary protein-to-creatinine ratio ≤0.11 (66.2 vs. 60.1 ml/minute, P = 0.004 and 63.8 vs. 59.0 ml/ minute, P = 0.049, at 12 and 24 months respectively). Graft and patient survival and the incidence of BPAR were similar in both groups. Th e discontinuation rate was higher in the SRL group at 12 months (15.7 vs. 9.5%, P = 0.013) but not at 24 months (25.8 vs. 20.0%, P = 0.07), with more adverse events during the fi rst 6 months after randomisation. Interestingly, the incidence of malignancies was reduced after SRL conversion (3.8 vs. 11% at 24 months, P <0.001) [9] .
A study of late conversion was performed with everolimus (EVL) [10] . In the ASCERTAIN study, 398 patients were randomised (mean 5.6 years after transplantation) to continue CNIs (cyclosporine or tacrolimus), to minimise CNI therapy with the addition of EVL or to convert to EVL. Th e mean measured GFR at 24 months, the primary endpoint, was not signifi cantly diff erent between the three groups, while proteinuria was signifi cantly higher in the EVL group at 12 months. A post-hoc analysis in patients with better baseline graft function (defi ned by Nankivell GFR >50 ml/minute) and who remained on the randomised treatment regimen has shown that the increase in GFR from baseline to month 24 was signifi cantly greater in the CNI elimination group than in control patients. Adverse events resulted in discontinuation for 28.3% of patients (P <0.001 vs. CNIfree patients) in the CNI elimination group, for 16.7% of patients in the CNI minimisation group (P = 0.02 vs. CNI-free patients) and for only 4% of patients who continued on a CNI-based regimen. Th e incidence of malignancies was not diff erent between the three groups (7.1%, 7.6% and 5.7%, respectively).
Th ese data suggest that the renal benefi t of a late conversion, 1 year or more after transplantation, is limited, except in patients with good renal function and without proteinuria. Renal biopsy prior to conversion is useful to select patients without mild to severe chronic renal allograft damage in whom conversion from CNIs to mTOR inhibitors can be accomplished safely and eff ectively.
Early conversion
Protocols of early CNI withdrawal with conversion to mTOR inhibitors in the maintenance phase have been performed with three main aims. Th e fi rst is to achieve optimal renal function at 1 year, because long-term graft and patient survival have been associated with 1-year renal function [11] [12] [13] . A 10 ml/minute decrease in GFR at 1 year is associated with a 2.1 odds ratio of kidney allograft loss 3 years after transplantation [14] .
Th e second aim is to reduce the incidence of viral infection, because previous studies have shown a low incidence of cytomegalovirus (CMV) infection in SRLtreated patients in comparison with CNI-treated patients [15] . A recent meta-analysis has shown that mTOR-inhibitor treatment, either alone or in combination with CNIs, signifi cantly reduced the incidence of CMV infection after organ transplantation, suggesting that CMV prophylaxis may be dispensable with the use of mTOR inhibitors [16] . Furthermore, a signifi cant increase in CMV-specifi c CD8 + T-cell count has been observed in EVL-treated renal recipients compared with CsA-treated patients [17] , and functional mTOR has recently been reported to be essential to CMV replication, suggesting a direct antiviral eff ect of mTOR inhibitors [18] . A study has suggested that mTOR inhibitors also reduce the incidence of BK virus infection after trans plantation [19] .
Th e third aim is to decrease the incidence of malignancies. Th is aim is supported by several studies showing that mTOR-inhibitor-based regimens could reduce the incidence of neoplasia [20] . Moreover, it has recently been shown that conversion from a CNI to SRL in kidney transplant patients following a fi rst skin cancer episode prevented the recurrence of skin cancer [21] . mTOR inhibitors have anti-neoplastic properties [22, 23] , in contrast to CNIs, which may induce cancer progression through mechanisms independent of host immunity [24] .
Early conversion has been used in the CONCEPT study [25] . Two hundred and thirty-fi ve nonimmunised patients transplanted with a deceased donor kidney received induction therapy with daclizumab and tri-therapy with CsA, MMF and steroids for 3 months. At 3 months, 192 patients with proteinuria <1 g/day and GFR ≥40 ml/ minute were randomised to either continue CsA (n = 97) or to convert to SRL (n = 95). MMF and steroids were planned to be discontinued at month 8.
Both groups were similar with respect to demographic and medical characteristics such as donor and recipient age, time of dialysis before transplantation, human leukocyte antigen and CMV matching, incidence of delayed graft function and GFR. Th e primary endpoint, estimated renal function (creatinine clearance) at 1 year according to the Cockcroft-Gault equation, was signifi cantly better in the SRL group (68.9 vs. 64.4 ml/minute, P = 0.017). Similar results were observed when the GFR was calculated according to the Modifi cation of Diet in Renal Disease formula (61.2 vs. 53.9 ml/minute, P = 0.002) or was measured using iohexol (67.3 vs. 60.3 ml/minute, P = 0.004). Patient and graft survival were excellent, with no death and only one graft loss, which occurred in the CsA group. CsA and SRL dosages and levels were adapted at 12 months to a mean daily dosage of 226 mg CsA, with mean blood levels 2 hours after dosing of 749 ng/ml, and to a mean daily dosage of 3.2 mg SRL with a mean trough level of 9.6 ng/ml.
Th e incidence of BPAR episodes was not signifi cantly higher in the SRL group (17% vs. 8%, P = 0.07), while steroids were withdrawn in 72% and 78% of patients, respectively. Of note, most episodes of BPAR occurred just after withdrawal of steroids in the SRL group. Th e incidence of adverse events (stomatitis, acne, diarrhoea, high triglyceride levels) was slightly increased in the SRL group (60% vs. 44%, P = 0.025) and more patients discontinued SRL (16% vs. 7%). Interestingly, haemoglobin, cholesterol, and proteinuria were similar in both groups. Th e number of patients with proteinuria >0.5 g/ day was also similar in both groups (12% in the SRL group vs. 9% in the CsA group). Some adverse events required adjustment of the MMF daily dose (1.7 g/day in the SRL group vs. 1.9 g/day in the CsA group, P <0.001). Aortic stiff ness and biomarkers of endothelial activation were studied in 44 patients enrolled in the CONCEPT study [26] . One year after transplantation, the carotid-to-femoral pulse-wave velocity was signifi cantly lower in the SRL group. In parallel, plasma levels of endothelin-1 decreased in the SRL group during the study, suggesting a benefi cial eff ect of SRL in preventing the development of cardiovascular complications after kidney trans plan tation. Conversion from CsA to SRL combined with MMF treatment 3 months after transplantation was therefore associated with an improvement in renal function with a good riskto-benefi t ratio.
Other studies have confi rmed the CONCEPT study results, irrespective of the mTOR inhibitor used. At 1 year, the renal benefi t of early conversion from CNIs to mTOR inhibitors has been observed with both SRL [27, 28] and EVL [29] . In the Spare-the-Nephron study, 299 patients were randomised 1 to 6 months after transplantation (mean 3.8 months) to continue CNI therapy or to convert to SRL (CsA, n = 31 or tacrolimus, n = 120) [28] . After 1 year, the mean percentage change from baseline of measured GFR was signifi cantly higher in the MMF/SRL group compared with the MMF/CNI group (24.4% vs. 5.2%, P = 0.012). Th e GFR, calculated according to Nankivell, was higher in the SRL group but the diff erence was not signifi cant (74.6 vs. 71.5 ml/ minute). In the SMART study, 161 patients with a low to moderate immunological risk were randomised 10 to 24 days after transplantation to convert to SRL or to continue CsA [27] . Th e primary endpoint, renal function estimated at 1 year according to Nankivell, was significantly better in the SRL group (64.5 vs. 53.4 ml/minute, P = 0.0019). In the ZEUS trial, 300 patients were randomised at 4.5 months to continue CsA or be converted to EVL [29] . At 1 year, the EVL regimen was associated with a better renal function evaluated accord ing to Nankivell (71.8 vs. 61.9 ml/minute, P <0.0001). Similar results were reported in the HERAKLES study at the last meeting of the American Congress of Transplantation [30] . Th e percentage of BPAR at 1 year was low and similar in both groups in these studies (11.3% vs. 9.5% in Spare-theNephron, 17% vs. 16% in SMART, 15% vs. 15% in ZEUS). Nevertheless, a signifi cantly increased incidence of BPAR was reported in the EVL group in the randomised period in the ZEUS trial (10% vs. 6%, P = 0.04). One-year graft and patient survival were similar in both groups in all studies. However, more adverse events and more discontinu ations were observed after conversion to mTOR inhibitors. Th ese studies (SMART, ZEUS, HERAKLES) assessing substitution of CsA with an mTOR inhibitor show that the renal benefi t at 1 year (about 8 to 10 ml/ minute) was similar to those observed in CONCEPT, whereas it was reduced with tacrolimus [28, 31] .
Heilman and colleagues have reported a prospective, randomised, nonblinded trial of early tacrolimus elimination at 1 month (60 and 62 patients in the tacrolimus and SRL groups, respectively) [31] . In this study, the measured GFR was similar in both groups at 1 and 2 years. Incidence of acute rejection was higher in the SRL group than in the tacrolimus group (Banff ≥IA: 13% vs. 5%, P = 0.15). Nevertheless, a very high percentage of withdrawal was observed in the SRL group (63% during the 2-year period). Other studies comparing the effi cacy and safety of mTOR inhibitors with tacrolimus do not support the advantages of mTORs [32] [33] [34] . Nevertheless, in all of these studies, mTOR inhibitors were used at trans plan tation (de novo) with a high percentage of early with drawal due to adverse events and sometimes subthera peutic dosing, especially in the Symphony study.
Early conversion to SRL with continuation of MMF may therefore represent an appropriate strategy for maintenance therapy in renal transplantation after careful screening at the time of transplantation. From these studies we can consider that the more suitable patients for early conversion are nonimmunised patients with good renal function (GFR >40 ml/minute), without previous severe acute rejection and subclinical rejection, in the absence of proteinuria >1 g/day and with donorspecifi c antibodies. Screening biopsy prior to conversion is important in selecting appropriate patients.
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Long-term clinical outcomes
Long-term clinical outcome studies are necessary to confi rm the short-term benefi ts of early CNI withdrawal. Patients who completed the initial 12 months of the SPIESSER and the CONCEPT studies were therefore enrolled in the post-SPIESSER and post-CONCEPT follow-up studies [35, 36] .
Th e 5-year results have been evaluated in 135 patients in the post-CONCEPT study (SRL, n = 65 and CsA, n = 70) and 130 patients in the post-SPIESSER study (SRL, n = 57 and CsA, n = 63). Patient survival and deathcensored graft survival were excellent in both studies and similar in both groups. In the SRL groups in the post-SPIESSER and post-CONCEPT studies, patient survival was 93% and 97.4% and death-censored graft survival was 87% and 97.4%. However, the benefi t on renal function in the SRL group, observed at 1 year, was maintained over 5 years in both studies (Figure 1 ). Renal function was signifi cantly better in the SRL group in both studies in the intent-to-treat populations. Th e 5-year mean GFR, estimated according to the Modifi cation of Diet in Renal Disease formula, was 59.1 versus 49.3 ml/ minute (P = 0.0012) in the post-CONCEPT study and 54.5 versus 45.3 ml/minute (P <0.01) in the post-SPIESSER study. Interestingly, this diff erence was more pronounced in patients who remained in their randomised arm at year 5 ( Figure 2) , with a 14.9 ml/minute and a 17.5 ml/minute diff erence in the CONCEPT and SPIESSER studies, respectively. Moreover, a negative GFR slope with a progressive deterioration of renal function was observed in patients who received CsA in both studies, but was not seen in the SRL groups.
Mean daily SRL and CsA doses and trough levels of SRL were similar in the SPIESSER and CONCEPT studies (SRL doses, 2.7 and 2.4 mg/day; SRL levels, 8.7 and 7.6 ng/ml; and CsA doses, 177 and 170 mg/day in the two studies respectively). In both studies, daily doses of MMF were adapted (CsA groups, 1,587 and 1,825 mg/ day; SRL groups, 1,403 and 1,542 mg/day in the two studies respectively). Interestingly, the percentage of steroid-free patients was higher in the SRL groups (76% and 73% vs. 69% and 61% in the two studies respectively). Th e occurrence of BPAR after 1 year was low in both studies (2 and 2 vs. 2 and 6 in the SRL and CsA groups from the SPIESSER and CONCEPT studies, respectively). Th e rate of patients with anti-human leukocyte antigen at 5 years was also similar (22% and 12.3% vs. 16% and 21.1% respectively). Th e 15% increased incidence of discontinuations observed at 1 year in the SRL groups was maintained at 5 years (40% and 44.6% vs. 24.2% and 21.6% respectively), with an increased incidence of side eff ects such as oedema, stomatitis, pneumonia and pyelonephritis. More patients with new-onset diabetes after transplantation were observed in the SRL group in the CONCEPT study but not in the SPIESSER study. Th e number of patients who developed malignancies (that is, skin cancers and nonskin malignancies) during follow-up was higher in the CsA groups in both studies in the ITT populations (9 and 9 vs. 4 and 6 respectively).
Lipid values (total cholesterol, low-density lipoproteincholesterol, high-density lipoprotein-cholesterol and triglycerides) and the percentage of patients receiving lipid-lowering agents were similar at 5 years in the two treatment groups in both studies. Th ere were no diff erences in haemoglobin values, either in the percentage of anaemic patients (defi ned as haemoglobin value <11 g/dl) or in the percentage of patients receiving an erythropoietin-stimulating agent between groups in both studies. However, mean red blood cell counts were higher in the SRL group, whereas mean corpuscular volumes were lower. Interestingly, mean proteinuria was similar in both groups at 5 years in both studies (0.5 and 0.4 g/24 hours vs. 0.4 and 0.4 g/24 hours). Moreover, the percentage of patients with protein uria >0.3 g/24 hours and the percentage of patients treated either with an angiotensin-converting-enzyme inhibitor and/or an angiotensin-receptor blocker were similar in both groups.
Th e 5-year results for CNI elimination with a SRL and MMF regimen therefore demonstrated that the renal benefi t observed 1 year after transplantation was maintained and even increased with stability in the GFR in patients remaining on assigned SRL therapy -compared with patients remaining on assigned CsA therapy, in whom the GFR was progressively declining. Moreover, fewer malignancies were observed. Th ese benefi ts were observed despite more SRL discontinuations due to early adverse events. Of note, similar long-term benefi t was observed with the CNI-free regimen [36] .
Conclusion
Early conversion to mTOR inhibitors in combination with MMF could be an appropriate strategy for main tenance therapy in renal transplant recipients with a low immunological risk, after careful screening at the time of conversion. Whether the benefi ts observed in these trials could infl uence long-term graft and patient survival remain to be determined.
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